Research findings indicated that about half of the cancer individuals experienced positive outcomes from ICIs like ipilimumab (anti-CTLA4) and nivolumab (anti-PD1) [37–39], which represents a promising advancement in treating cancer. Here, PDCD1 is linked to cancer.